ValuEngine upgraded shares of Curis, Inc. (NASDAQ:CRIS) from a sell rating to a hold rating in a report released on Thursday morning.
A number of other research firms also recently weighed in on CRIS. Zacks Investment Research raised shares of Curis from a sell rating to a hold rating in a research report on Tuesday, March 14th. Cowen and Company reissued a buy rating on shares of Curis in a research report on Friday, May 5th. Finally, FBR & Co set a $6.00 price target on shares of Curis and gave the stock a buy rating in a research report on Saturday, March 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $5.88.
Shares of Curis (NASDAQ CRIS) traded up 0.95% during mid-day trading on Thursday, hitting $2.13. 295,925 shares of the stock traded hands. Curis has a one year low of $1.47 and a one year high of $3.72. The stock has a 50-day moving average of $1.82 and a 200 day moving average of $2.54. The stock’s market cap is $306.23 million.
Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.02. Curis had a negative return on equity of 163.29% and a negative net margin of 841.05%. The company had revenue of $2.13 million for the quarter, compared to analyst estimates of $1.98 million. During the same period in the previous year, the business posted ($0.07) EPS. The firm’s quarterly revenue was up 23.1% compared to the same quarter last year. Equities analysts predict that Curis will post ($0.40) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/06/23/curis-inc-cris-upgraded-to-hold-by-valuengine.html.
In other Curis news, Director James R. Mcnab sold 146,694 shares of Curis stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $2.61, for a total value of $382,871.34. Following the completion of the transaction, the director now owns 912,426 shares of the company’s stock, valued at $2,381,431.86. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director James R. Mcnab sold 110,322 shares of Curis stock in a transaction on Monday, April 24th. The stock was sold at an average price of $2.59, for a total transaction of $285,733.98. Following the completion of the transaction, the director now directly owns 1,357,147 shares of the company’s stock, valued at approximately $3,515,010.73. The disclosure for this sale can be found here. In the last ninety days, insiders sold 450,000 shares of company stock valued at $1,101,973. 4.07% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in CRIS. Bank of America Corp DE increased its position in Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares in the last quarter. Prudential Financial Inc. acquired a new position in Curis during the first quarter worth approximately $105,000. Dynamic Technology Lab Private Ltd acquired a new position in Curis during the fourth quarter worth approximately $106,000. A.R.T. Advisors LLC acquired a new position in Curis during the fourth quarter worth approximately $116,000. Finally, Oxford Asset Management acquired a new position in Curis during the fourth quarter worth approximately $138,000. 51.63% of the stock is owned by hedge funds and other institutional investors.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.